The role of the class II transactivator (CIITA) in MHC class I and II regulation and graft rejection in kidney

被引:11
|
作者
Sims, TN
Afrouzian, M
Urmson, J
Zhu, LF
Halloran, PF [1 ]
机构
[1] Univ Alberta, Dept Med Microbiol & Immunol, Heritage Med Res Ctr 250, Edmonton, AB T6G 2S2, Canada
[2] Univ Alberta, Dept Med, Div Nephrol & Immunol, Heritage Med Res Ctr 250, Edmonton, AB T6G 2S2, Canada
[3] Univ Alberta, Dept Lab Med & Pathol, Heritage Med Res Ctr 250, Edmonton, AB T6G 2S2, Canada
[4] Univ Alberta, Dept Surg, Heritage Med Res Ctr 250, Edmonton, AB T6G 2S2, Canada
关键词
antigen presentation; Banff schema; CIITA; graft rejection; MHC regulation;
D O I
10.1034/j.1600-6143.2001.001003211.x
中图分类号
R61 [外科手术学];
学科分类号
摘要
Class II transactivator (CIITA) induces transcription of MHC class II genes, and induces class I in some cell lines. We examined the effect of CIITA deficiency on class I and II expression in mouse kidney. In CIITA knockout (CIITAKO) mice, basal class II was absent, but class I levels were mildly but significantly increased. Allogeneic stimulation or ischemic injury increased class I and II expression in kidneys of control (wild-type, WT) mice but induced only class I in CII-TAKO mice. Thus, in kidney, all basal and induced class II expression was CIITA-dependent, but neither basal nor induced class I was CIITA-dependent. Rejecting kidney allografts from CIITAKO mice in CBA hosts manifested intense induction of donor class I but no donor class II expression. Rejecting kidneys from both WT and CIITAKO donors showed predominantly CD8 T-cell infiltration at days 7 and 21, with increasing tubulitis and arteritis at day 21. CIITAKO kidneys showed fewer infiltrating cells than WT kidneys at day 21. Thus CIITA-deficient kidneys have no basal and induced class II expression but display intense induction of class I expression, and evoke typical rejection lesions, although some indices of infiltration are reduced at day 21.
引用
收藏
页码:211 / 221
页数:11
相关论文
共 50 条
  • [41] The MHC class II transactivator (CIITA): A "Physiologic" drug against HIV-1 replication
    Tosi, Giovanna
    Barbaro, Andrea De Lerma
    Mortara, Lorenzo
    Accolla, Roberto S.
    RETROVIROLOGY, 2005, 2 (Suppl 1)
  • [42] MHC class II transactivator (CIITA) expression is upregulated in multiple myeloma cells by IFN-γ
    Zhao, Mojun
    Flynt, Frederick L.
    Hong, Mei
    Chen, Han
    Gilbert, Carolyn A.
    Briley, Nicole T.
    Bolick, Sophia C.
    Wright, Kenneth L.
    Piskurich, Janet F.
    MOLECULAR IMMUNOLOGY, 2007, 44 (11) : 2923 - 2932
  • [43] Failure of MHC class II expression in neonatal alveolar macrophages: potential role of class II transactivator
    Lee, PT
    Holt, PG
    McWilliam, AS
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2001, 31 (08) : 2347 - 2356
  • [44] The MHC class II transactivator (CIITA): A physiologic inhibitor of HTLV-2 retroviral infection
    Tosi, Giovanna
    Pilotti, Elisabetta
    Barbaro, Andrea De Lerma
    Mortara, Lorenzo
    Casoli, Claudio
    Accolla, Roberto S.
    RETROVIROLOGY, 2005, 2 (Suppl 1)
  • [45] The MHC class II transactivator (CIITA): A physiologic inhibitor of HTLV-2 retroviral infection
    Tosi, Giovanna
    Pilotti, Elisabetta
    Barbaro, Andrea De Lerma
    Mortara, Lorenzo
    Casoli, Claudio
    Accolla, Roberto S.
    RETROVIROLOGY, 2005, 2
  • [46] Revisiting the specificity of the MHC class II transactivator CIITA in classical murine dendritic cells in vivo
    Anderson, David A., III
    Grajales-Reyes, Gary E.
    Satpathy, Ansuman T.
    Vasquez Hueichucura, Carlos E.
    Murphy, Theresa L.
    Murphy, Kenneth M.
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2017, 47 (08) : 1317 - 1323
  • [47] The MHC Class II Transactivator (CIITA): A "Physiologic" Drug Against HIV-1 Replication
    Giovanna Tosi
    Andrea De Lerma Barbaro
    Lorenzo Mortara
    Roberto S Accolla
    Retrovirology, 2
  • [48] The MHC class II transactivator CIITA acts as a restriction factor for HIV in human myeloid cells
    Forlani, Greta
    Ghezzi, Silvia
    Tedeschi, Alessandra
    Poli, Guido
    Tosi, Giovanna
    Accolla, Roberto
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2017, 74 : 78 - 78
  • [49] The Molecular and Cellular Basis of Tumor Rejection After Vaccination With Mammary Adenocarcinoma Cells Transduced With the MHC Class II Transactivator CIITA
    Lorenzo Mortara
    Paola Castellani
    Raffaella Meazza
    Giovanna Tosi
    Andrea De Lerma Barbaro
    Francesco A Procopio
    Luciano Zardi
    Silvano Ferrini
    Roberto S Accolla
    Retrovirology, 2
  • [50] Class II transactivator: is it a master switch for MHC class II gene expression?
    Chang, CH
    Roys, S
    Gourley, T
    MICROBES AND INFECTION, 1999, 1 (11) : 879 - 885